SCHEDULE: FMR LLC Maintains Significant Stake in Alnylam Pharma
Beneficial Ownership Report
FMR LLC and its affiliates, including Abigail P. Johnson, reported a 12.8% beneficial ownership stake in Alnylam Pharmaceuticals Inc. as of September 30, 2025.
Summary
- FMR LLC and its affiliates, including Abigail P. Johnson, beneficially own 16,834,094.74 shares of Alnylam Pharmaceuticals Inc. common stock.
- This represents 12.8% of Alnylam Pharmaceuticals Inc.'s total outstanding common stock.
- FMR LLC holds sole voting power over 16,297,654.18 shares and sole dispositive power over all 16,834,094.74 shares.
- The filing is an Amendment No. 22 to Schedule 13G, indicating ongoing reporting of their significant stake.
- The securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of Alnylam Pharmaceuticals Inc.
Sentiment
Score: 7
Explanation: The filing indicates a continued significant beneficial ownership stake by a major institutional investor, FMR LLC, in Alnylam Pharmaceuticals Inc. This suggests ongoing confidence in the company's value proposition and long-term prospects from a prominent investment firm.
Positives
- A significant 12.8% stake by a major institutional investor like FMR LLC can signal confidence in Alnylam Pharmaceuticals Inc.'s long-term prospects.
- The holding is stated to be in the ordinary course of business, suggesting a passive investment rather than an activist stance that could create uncertainty.
Risks
- No specific risks related to Alnylam Pharmaceuticals Inc. are mentioned in this filing.
Future Outlook
No forward-looking statements or guidance regarding Alnylam Pharmaceuticals Inc.'s future performance are provided in this beneficial ownership report.
Industry Context
This filing reflects a significant, stable institutional investment in the biotechnology sector. Large holdings by entities like FMR LLC are common for established pharmaceutical and biotech companies, indicating long-term investment interest rather than short-term speculation. Alnylam Pharmaceuticals operates in a competitive and innovation-driven industry, and such institutional backing can be viewed positively.
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
| Internal Governance Disclosure | The filing details the internal governance structure of FMR LLC, noting that members of the Johnson family, including Abigail P. Johnson, are predominant owners of Series B voting common shares (49% voting power) and have a shareholders' voting agreement, forming a controlling group for FMR LLC. | NA | This provides transparency into the control structure of the reporting entity, FMR LLC, but does not directly impact Alnylam Pharmaceuticals Inc.'s corporate governance. |
Stakeholder Impact
- Shareholders: May view the continued significant institutional ownership as a positive signal of confidence in the company.
- Management: The stable institutional holding may provide a degree of stability and long-term focus.
Key Dates
| Date | Description |
|---|---|
| 2023-01-03 | Effective date of Power of Attorney for FMR LLC and its direct and indirect subsidiaries. |
| 2023-01-10 | Date of Schedule 13G filing by FMR LLC, accession number -23-000003, referenced for FMR LLC's Power of Attorney. |
| 2023-01-26 | Effective date of Power of Attorney for Abigail P. Johnson. |
| 2023-01-31 | Date of Schedule 13G filing by FMR LLC, accession number -23-000038, referenced for Abigail P. Johnson's Power of Attorney. |
| 2025-09-30 | Date of event which requires filing of this statement (reporting period end date). |
| 2025-11-04 | Signature date of the Schedule 13G filing. |
Recommendation
holdThe filing is a routine beneficial ownership report (Schedule 13G Amendment No. 22) from a major institutional investor, FMR LLC, indicating a continued significant stake of 12.8% in Alnylam Pharmaceuticals Inc. While a large institutional holding generally signals confidence, this filing does not contain new information regarding the company's operational performance, financial health, or strategic direction that would warrant a change in investment recommendation. It primarily confirms an existing, substantial position, suggesting a 'hold' for investors who already have a position, pending further operational updates from Alnylam.
Keywords
Alnylam Pharmaceuticals, ALNY, FMR LLC, Abigail P. Johnson, Beneficial Ownership, Institutional Investor, Schedule 13G, Common Stock, Biotechnology, Pharmaceuticals
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.